Genes May Help Identify Severe Male Infertility - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Genes May Help Identify Severe Male Infertility

Three amino acid metabolism genes showed diagnostic signal in testicular tissue, though small sample sizes and computational methods limit clinical translation.

  • By

  • Mouj Hijazi

  • May 15, 2026

  • 3 min

Share

Objective:

To identify potential diagnostic biomarkers for nonobstructive azoospermia (NOA) through gene expression analysis, which could improve noninvasive diagnosis and clinical management.

Key Findings:
  • AKT1, ASNS, and SHC1 showed AUC values greater than 0.7 in both training and validation data sets.
  • Significant upregulation of AKT1 and SHC1 in NOA patients was observed, while ASNS showed lower expression without statistical significance, indicating a need for further investigation.
  • Functional enrichment analyses indicated involvement in male gamete generation and spermatogenesis, with potential links to immune dysregulation.
Interpretation:

The identified biomarkers may play a role in germ cell development and could be linked to immune dysregulation in NOA pathophysiology, suggesting avenues for future research.

Limitations:
  • Small sample sizes in public gene-expression data sets limit the robustness of findings.
  • Tissue-based sampling may restrict generalizability to broader populations.
  • Limited experimental validation raises concerns about potential overfitting and the reliability of results.
Conclusion:

The findings are preliminary and require larger studies for validation before clinical application in diagnosing NOA, emphasizing the need for further research.

Original Source(s)

Genes May Help Identify Severe Male Infertility

  • by Mouj Hijazi

  • May 15, 2026

Related Content

Menstrual Fluid May Aid in Endometriosis Detection

Single-nucleus sequencing of menstrual fluid identified epithelial gene signatures and prioritized five candidate biomarkers that warrant validation in larger studies.

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.